Skip to main content

F-star Therapeutics, Inc.

FSTXDelisted Mar 9, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001566373

F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
59
Q4 2022, +6 vs. previous quarter
13F value
$57.8M
Reported value at the end of Q4 2022
Superinvestors holding
1
At the end of Q4 2022

From SEC filings, in USD.

Revenue, FY2021
$21.2M
+88.1% year over year
Net income, FY2021
-$31.3M
No comparable prior period
Free cash flow, FY2021
-$27.9M
No comparable prior period
Revenue, Q3 FY2022
$1.13M
+49.8% year over year

Revenue flow, FY2021

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2021: $31.3M (147.8% of revenue).

Superinvestors holding FSTX, Q4 2022

Go to the superinvestors tab

1 superinvestor reports holding F-star Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Fairfax Financial

Prem Watsa

<0.1%

F-star Therapeutics, Inc.'s share of the portfolio

Shares
49,399
Value
$311.7K

Latest insider trades

See all insider trades

Open-market purchases and sales by F-star Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 4, 2021 (view filing)Nov 22 daysKayitalire LouisChief Medical OfficerSSale−64$6.83−$436.84−0.1%54.3K after2 lots
Oct 6, 2021 (view filing)Oct 42 daysKayitalire LouisChief Medical OfficerSSale−64$7.23−$462.72−0.1%54.3K after
Jul 7, 2021 (view filing)Jul 25 daysKayitalire LouisChief Medical OfficerSSale−1.05K$8.43−$8.89K−1.9%54.4K after

Top 10 13F holders, Q4 2022

See all 59 holders

The largest institutional positions in F-star Therapeutics, Inc. at the end of Q4 2022; share changes are against Q3 2022.

Institutions holding FSTX in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Armistice Capital, LLC1,000,000$6.32M0.17%+1,000,000New
Rock Springs Capital Management LP751,889$4.75M0.11%00.0%Unchanged
Trium Capital LLP679,744$4.30M1.97%+679,744New
Atlas Venture Life Science Advisors, LLC599,524$3.79M0.46%00.0%Unchanged
DAFNA Capital Management LLC576,881$3.65M1.03%00.0%Unchanged
Atlas Venture Advisors, Inc.574,996$3.63M1.25%00.0%Unchanged
Weiss Asset Management LP548,189$3.46M0.17%+548,189New
Russell Investments Group, Ltd.432,125$2.73M0.01%−58,587−11.9%Reduced
Crystalline Management Inc.375,000$2.37M1.19%+375,000New
BlackRock Inc.297,433$1.88M0.00%−370−0.1%Reduced